These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38087729)

  • 1. [Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)].
    Rea D; Cayssials E; Charbonnier A; Coiteux V; Etienne G; Goldwirt L; Guerci-Bresler A; Huguet F; Legros L; Roy L; Nicolini FE
    Bull Cancer; 2024 Jan; 111(1):87-96. PubMed ID: 38087729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
    Cortes JE; Apperley JF; DeAngelo DJ; Deininger MW; Kota VK; Rousselot P; Gambacorti-Passerini C
    J Hematol Oncol; 2018 Dec; 11(1):143. PubMed ID: 30587215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
    Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
    Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.
    Lipton JH; Brümmendorf TH; Sweet K; Apperley JF; Cortes JE
    Ann Hematol; 2024 Sep; 103(9):3429-3442. PubMed ID: 39023573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.
    Khoury HJ; Gambacorti-Passerini C; Brümmendorf TH
    Ann Oncol; 2018 Mar; 29(3):578-587. PubMed ID: 29385394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
    Brivio E; Pennesi E; Willemse ME; Huitema ADR; Jiang Y; van Tinteren HDR; van der Velden VHJ; Beverloo BH; den Boer ML; Rammeloo LAJ; Hudson C; Heerema N; Kowalski K; Zhao H; Kuttschreuter L; Bautista Sirvent FJ; Bukowinski A; Rizzari C; Pollard J; Murillo-Sanjuán L; Kutny M; Zarnegar-Lumley S; Redell M; Cooper S; Bertrand Y; Petit A; Krystal J; Metzler M; Lancaster D; Bourquin JP; Motwani J; van der Sluis IM; Locatelli F; Roth ME; Hijiya N; Zwaan CM
    J Clin Oncol; 2024 Mar; 42(7):821-831. PubMed ID: 38033284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
    Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
    Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
    Yüzbaşıoğlu MB; Eşkazan AE
    Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467
    [No Abstract]   [Full Text] [Related]  

  • 10. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
    Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
    Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
    Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
    Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
    Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Unkrig C; Enzmann H; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2014 Apr; 19(4):421-5. PubMed ID: 24668331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
    Keller-V Amsberg G; Brümmendorf TH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
    Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
    Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G; Schafhausen P; Brummendorf TH
    Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
    Gambacorti-Passerini C; Cortes JE; Lipton JH; Kantarjian HM; Kim DW; Schafhausen P; Crescenzo R; Bardy-Bouxin N; Shapiro M; Noonan K; Leip E; DeAnnuntis L; Brümmendorf TH; Khoury HJ
    Haematologica; 2018 Aug; 103(8):1298-1307. PubMed ID: 29773593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.